Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Hexarelin cycle length: what human studies ran

Not approved — research use onlyBLimited human data
Short answer: there is no established Hexarelin cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Hexarelin combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Hexarelin cycle length?
No. We found no human studies that report a treatment duration for Hexarelin.
What is the longest human study of Hexarelin?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Hexarelin dosing reference Full research page

References

  1. Drugs@FDA application data queried through openFDA for hexarelin and examorelin (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  2. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  3. The cardiovascular action of hexarelin J Geriatr Cardiol. 2014
  4. Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases Endocrine. 2015
  5. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone J Clin Endocrinol Metab. 2001
  6. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy Eur J Heart Fail. 2002
  7. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery Eur J Pharmacol. 2002
  8. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging Eur J Endocrinol. 1996
  9. The Safety and Efficacy of Growth Hormone Secretagogues Sex Med Rev. 2018
  10. PubChem compound record for hexarelin (CID 6918297; CAS 140703-51-1) PubChem. 2026